Oral cavity disintegration tablet for treating gout and its preparation method

Abstract

The invention relates to a dosage form of medicine, in particular to an orally disintegrating tablet for treating gout and a preparation method thereof. The orally disintegrating tablet for treating gout of the present invention includes a pharmaceutical active ingredient and auxiliary materials. The pharmaceutical active ingredient is allopurinol, and the auxiliary materials include Disintegrants, soluble polyols, fillers, and penetrating agents, among which allopurinol accounts for 20% to 50% of the tablet weight, disintegrants account for 5% to 15%, and soluble polyols account for 30% to 60%, Fillers account for 10% to 30%, penetrants account for 1% to 5%, lubricants account for 0.5% to 1.5%, sweeteners account for 0.5% to 3%, and flavors account for 0.5% to 3%. Compared with common oral preparations, the present invention has rapid onset of effect because the gastrointestinal tract mucosa is widely covered by the fast-disintegrating medicine. Moreover, the drug can be absorbed through the oral mucosa, eliminating the first-pass effect, improving bioavailability, and reducing irritation to the gastrointestinal tract.

Description

technical field [0001] The invention relates to a dosage form of medicine, in particular to an orally disintegrating tablet for treating gout and a preparation method thereof. Background technique [0002] Gout is a group of heterogeneous diseases caused by excessive blood uric acid and deposition in joints, soft tissues, bone marrow, kidneys, etc. caused by long-term purine metabolism disorders. It is more common in middle-aged, elderly and gastric patients. . The clinical features are: uric acidemia, recurrent episodes of characteristic acute arthritis, uric acid crystals can be found in the white blood cells of the synovial fluid of the joints, tophi formation, and severe cases can lead to joint mobility disorders and deformities, renal uric acid stones and / or gouty Renal parenchymal disease. [0003] Currently, there is no cure for gout. According to the pathogenesis of gout, drugs for the treatment of gout can produce a therapeutic effect by inhibiting the synthesis ...

AI Technical Summary

Problems solved by technology

At present, most of the dosage forms of allopurinol in the market have problems such as slow onset of action, low bioavailability, and large gastrointestinal irritation.